Search results
Results From The WOW.Com Content Network
Flex Pharma stock was on the rise today following news of a merger with Salarius Pharmaceuticals. Source: amtec.us.com The deal will have a wholly owned subsidiary of Flex Pharma (NASDAQ:FLKS ...
Salarius Pharmaceuticals Inc (NASDAQ:SLRX) was trading 0.1% higher from the previous closing price. A Form 4 filing filed with the SEC on Monday, August 17 showed that Exec VP Finance CFO ...
HOUSTON and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and Decoy Therapeutics, Inc., a privately held preclinical biopharmaceutical company engineering the next ...
Embattled Flex Pharma Inc (NASDAQ: FLKS) announced a deal Friday to merge with privately held Salarius Pharma, an oncology company targeting the epigenetic causes of cancer. Following the closing ...
The NASDAQ Biotechnology Index is a stock market index made up of securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either the Biotechnology or the Pharmaceutical industry. [1] A list of the 225 components of the index is published online.
Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.
G.D. Searle, LLC is a wholly owned subsidiary of Pfizer. [1] It is currently a trademark company and subsidiary of Pfizer, operating in more than 43 countries. It also operates as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle).
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has initiated the expansion stage of its ongoing Phase 1/2 clinical trial evaluating its lead candidate seclidemstat in patients with relapsed and ...